Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future.

about

Future perspectives in target-specific immunotherapies of myasthenia gravis Regulatory T cells in multiple sclerosis and myasthenia gravis.Immunology of stiff person syndrome and other GAD-associated neurological disorders.Factors affecting outcome in myasthenia gravis.

P2860

Q26776225-9ACCD7F2-1CD0-4A6A-87C1-2D44CBD82C08 Q33784969-B45CB59E-1361-4B29-AE16-B73587B23CBD Q38156224-825B3D51-6948-40BC-AB66-CD7F2F0E4CE6 Q51725426-C5399EE6-023A-4570-A011-91A14C56F456

P2860

Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future.

Item

http://www.wikidata.org/entity/Q38068530

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Biologics and other novel appr ...... gravis: a view to the future.

@en

type

Item

label

Biologics and other novel appr ...... gravis: a view to the future.

@en

prefLabel

Biologics and other novel appr ...... gravis: a view to the future.

@en

P1476

Biologics and other novel appr ...... gravis: a view to the future.

@en

P2093

Marinos C Dalakas

http://www.w3.org/2001/XMLSchema#string

P2860

Current and emerging therapies in multiple sclerosis: a systematic review

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Campath-1H monoclonal antibody therapy.

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.

Immunotherapy of inflammatory myopathies: practical approach and future prospects.

Immunotherapy in autoimmune neuromuscular disorders.

Basic principles of immunotherapy for neurologic diseases.

The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.

Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1749-6632.2012.06832.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

1274

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23252891

http://www.w3.org/2001/XMLSchema#string

P921

myasthenia gravis

Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future.

about

P2860

P2860

Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921